Stock events for Immunome, Inc. (IMNM)
Immunome's stock price has increased by 114.99% over the past six months, reaching $21.86 as of February 27, 2026, a 144.52% increase from March 3, 2025. Key events include positive Phase 3 RINGSIDE trial results for varegacestat, the Q4 2025 earnings report revealing a net loss of $41.577 million, analyst ratings with buy recommendations and price targets, and insider buying by Philip Tsai.
Demand Seasonality affecting Immunome, Inc.’s stock price
As a clinical-stage biopharmaceutical company, Immunome, Inc. does not currently have commercialized products or services with established demand seasonality. The demand for its future products will be driven by medical needs, regulatory approvals, and market adoption rather than seasonal patterns.
Overview of Immunome, Inc.’s business
Immunome, Inc. is a clinical-stage biotechnology company focused on developing antibody-based therapeutics for cancer and infectious diseases, utilizing a human memory B cell platform. The company operates in the Healthcare sector, specifically in the Biotechnology industry, with a portfolio including immunotherapies, radioligand therapies, and Antibody-Drug Conjugates (ADCs). Key pipeline candidates include Varegacestat, an investigational small molecule gamma secretase inhibitor in Phase III for desmoid tumors with positive topline results; IMM-ONC-01, an antibody targeting interleukin-38 (IL-38) for various solid tumors; IM-1021, a ROR1-targeted ADC in Phase 1 showing objective responses in B-cell lymphoma patients; IM-3050, a FAP-targeted lutetium-177 radioligand therapy with a planned Phase 1 study; and preclinical solid tumor ADCs (IM-1617, IM-1340, IM-1335) advancing towards IND submissions.
IMNM’s Geographic footprint
Immunome, Inc. primarily operates in the U.S., with its headquarters located in Bothell, Washington.
IMNM Corporate Image Assessment
Immunome's brand reputation is tied to its clinical pipeline progress and financial performance. Positive Phase 3 RINGSIDE trial results were a significant positive event. Analyst ratings are generally positive, with a "Moderate Buy" average rating. The company has a history of losses and has not yet achieved profitability, and recent earnings reports have shown wider losses and a decline in collaboration revenue.
Ownership
Immunome, Inc. has significant institutional ownership, with approximately 93.86% of the company's shares held by institutional investors and 1.25% held by individuals. Major institutional shareholders include Fmr Llc, BlackRock, Inc., Point72 Asset Management, L.P., Vanguard Group Inc, Redmile Group, LLC, Enavate Sciences GP, LLC, Primecap Management Co/ca/, State Street Corp, Driehaus Capital Management Llc, and T. Rowe Price Investment Management Inc.
